Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

AVAPRITINIB for Malignant connective tissue neoplasm: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 73 adverse event reports in the FDA FAERS database where AVAPRITINIB was used for Malignant connective tissue neoplasm.

Most Reported Side Effects for AVAPRITINIB

Side Effect Reports % Deaths Hosp.
Fatigue 1,527 15.1% 3 120
Off label use 1,138 11.3% 49 101
Nausea 1,033 10.2% 5 93
Diarrhoea 886 8.8% 6 86
Swelling face 481 4.8% 0 37
Memory impairment 467 4.6% 6 48
Dizziness 458 4.5% 1 38
Vomiting 456 4.5% 2 63
Headache 454 4.5% 2 44
Asthenia 433 4.3% 8 79
Platelet count decreased 428 4.2% 9 54
Peripheral swelling 419 4.1% 4 46
Rash 400 4.0% 0 30
Lacrimation increased 396 3.9% 1 24
Decreased appetite 391 3.9% 6 44

Other Indications for AVAPRITINIB

Systemic mastocytosis (3,988) Gastrointestinal stromal tumour (3,345) Indolent systemic mastocytosis (843) Advanced systemic mastocytosis (594) Haematopoietic neoplasm (417) Product used for unknown indication (279) Mastocytoma (244) Malignant mast cell neoplasm (167) Brain neoplasm malignant (122) Acute myeloid leukaemia (104)

Other Drugs Used for Malignant connective tissue neoplasm

PAZOPANIB (417) CABOZANTINIB S-MALATE (188) RIPRETINIB (139) IMATINIB (80) TAZEMETOSTAT HYDROBROMIDE (72) NIVOLUMAB (60) PALBOCICLIB (50) SUNITINIB MALATE (39) IPILIMUMAB (24) REGORAFENIB (21)

Related Pages

AVAPRITINIB Full Profile All Malignant connective tissue neoplasm Drugs AVAPRITINIB Demographics AVAPRITINIB Timeline